127 related articles for article (PubMed ID: 30316896)
21. Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI.
Sheridan AD; Nath SK; Syed JS; Aneja S; Sprenkle PC; Weinreb JC; Spektor M
AJR Am J Roentgenol; 2018 Feb; 210(2):347-357. PubMed ID: 29112469
[TBL] [Abstract][Full Text] [Related]
22. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
[No Abstract] [Full Text] [Related]
23. Variation in Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Outcomes in Asian American Men: A Multicenter Study.
Gross MD; Marks LS; Sonn GA; Green DA; Wang GJ; Shoag JE; Cabezon E; Margolis DJ; Robinson BD; Hu JC
J Urol; 2020 Mar; 203(3):530-536. PubMed ID: 31502942
[TBL] [Abstract][Full Text] [Related]
24. Prostate zonal anatomy correlates with the detection of prostate cancer on multiparametric magnetic resonance imaging/ultrasound fusion-targeted biopsy in patients with a solitary PI-RADS v2-scored lesion.
Syed JS; Nguyen KA; Nawaf CB; Bhagat AM; Huber S; Levi A; Humphrey P; Weinreb JC; Schulam PG; Sprenkle PC
Urol Oncol; 2017 Sep; 35(9):542.e19-542.e24. PubMed ID: 28501565
[TBL] [Abstract][Full Text] [Related]
25. Which men with non-malignant pathology at magnetic resonance imaging-targeted prostate biopsy and persistent PI-RADS 3-5 lesions should repeat biopsy?
Castellani D; Pace G; Cecchini S; Franzese C; Cicconofri A; Romagnoli D; Del Rosso A; Possanzini M; Paci E; Dellabella M; Pierangeli T
Urol Oncol; 2022 Oct; 40(10):452.e9-452.e16. PubMed ID: 35871992
[TBL] [Abstract][Full Text] [Related]
26. The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men.
Kongnyuy M; Sidana A; George AK; Muthigi A; Iyer A; Fascelli M; Kadakia M; Frye TP; Ho R; Mertan F; Minhaj Siddiqui M; Su D; Merino MJ; Turkbey B; Choyke PL; Wood BJ; Pinto PA
Urol Oncol; 2016 Jun; 34(6):254.e15-21. PubMed ID: 26905304
[TBL] [Abstract][Full Text] [Related]
27. MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and Data System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI.
Sheridan AD; Nath SK; Aneja S; Syed JS; Pahade J; Mathur M; Sprenkle P; Weinreb JC; Spektor M
AJR Am J Roentgenol; 2018 May; 210(5):W218-W225. PubMed ID: 29489409
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of magnetic resonance imaging fusion-targeted biopsy of prostate imaging reporting and data system 3 lesions.
Kim TJ; Lee MS; Hwang SI; Lee HJ; Hong SK
World J Urol; 2019 Aug; 37(8):1581-1586. PubMed ID: 30460594
[TBL] [Abstract][Full Text] [Related]
29. Three Tesla Multiparametric Magnetic Resonance Imaging: Comparison of Performance with and without Endorectal Coil for Prostate Cancer Detection, PI-RADS™ version 2 Category and Staging with Whole Mount Histopathology Correlation.
Mirak SA; Shakeri S; Bajgiran AM; Felker ER; Sung KH; Asvadi NH; Khoshnoodi P; Markovic D; Ponzini D; Ahuja P; Sisk A; Reiter RE; Lu D; Raman SS
J Urol; 2019 Mar; 201(3):496-502. PubMed ID: 30273608
[TBL] [Abstract][Full Text] [Related]
30. Minimum Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Cores Needed for Prostate Cancer Detection: Multivariable Retrospective, Lesion Based Analyses of Patients Treated with Radical Prostatectomy.
Leyh-Bannurah SR; Kachanov M; Beyersdorff D; Tian Z; Karakiewicz PI; Tilki D; Fisch M; Maurer T; Graefen M; Budäus L
J Urol; 2020 Feb; 203(2):299-303. PubMed ID: 31483694
[TBL] [Abstract][Full Text] [Related]
31. Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort-How Many Clinically Significant Prostate Cancers are Missed?
Feuer Z; Meng X; Rosenkrantz AB; Kasivisvanathan V; Moore CM; Huang R; Deng FM; Lepor H; Wysock JS; Huang WC; Taneja SS
J Urol; 2021 Mar; 205(3):740-747. PubMed ID: 33026927
[TBL] [Abstract][Full Text] [Related]
32. MRI-guided in-bore biopsy for prostate cancer: what does the evidence say? A case series of 554 patients and a review of the current literature.
Pokorny M; Kua B; Esler R; Yaxley J; Samaratunga H; Dunglison N; Gianduzzo T; Coughlin G; Holt R; Laing B; Ault D; Brown N; Parkinson R; Thompson L
World J Urol; 2019 Jul; 37(7):1263-1279. PubMed ID: 30255394
[TBL] [Abstract][Full Text] [Related]
33. Utilizing lesion diameter and prostate specific antigen density to decide on magnetic resonance imaging guided confirmatory biopsy of prostate imaging reporting and data system score three lesions in African American prostate cancer patients managed with active surveillance.
Alanee S; Deebajah M; Dabaja A; Peabody J; Menon M
Int Urol Nephrol; 2022 Apr; 54(4):799-803. PubMed ID: 35138582
[TBL] [Abstract][Full Text] [Related]
34. Defining Novel and Practical Metrics to Assess the Deliverables of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy.
Ristau BT; Chen DYT; Ellis J; Malhotra A; DeMora L; Parsons RB; Milestone B; Brody M; Viterbo R; Greenberg R; Smaldone M; Uzzo R; Anaokar J; Kutikov A
J Urol; 2018 Apr; 199(4):969-975. PubMed ID: 28988963
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
36. Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center.
Hermie I; Van Besien J; De Visschere P; Lumen N; Decaestecker K
Eur J Radiol; 2019 May; 114():92-98. PubMed ID: 31005183
[TBL] [Abstract][Full Text] [Related]
37. African American Men have Increased Risk of Prostate Cancer Detection Despite Similar Rates of Anterior Prostatic Lesions and PI-RADS Grade on Multiparametric Magnetic Resonance Imaging.
Patel HD; Doshi CP; Koehne EL; Hart S; Van Kuiken M; Quek ML; Flanigan RC; Gupta GN
Urology; 2022 May; 163():132-137. PubMed ID: 34302832
[TBL] [Abstract][Full Text] [Related]
38. Interreader Agreement of Prostate Imaging Reporting and Data System Version 2 Using an In-Bore MRI-Guided Prostate Biopsy Cohort: A Single Institution's Initial Experience.
Glazer DI; Mayo-Smith WW; Sainani NI; Sadow CA; Vangel MG; Tempany CM; Dunne RM
AJR Am J Roentgenol; 2017 Sep; 209(3):W145-W151. PubMed ID: 28657843
[TBL] [Abstract][Full Text] [Related]
39. Do patients with a PI-RADS 5 lesion identified on magnetic resonance imaging require systematic biopsy in addition to targeted biopsy?
Drobish JN; Bevill MD; Tracy CR; Sexton SM; Rajput M; Metz CM; Gellhaus PT
Urol Oncol; 2021 Apr; 39(4):235.e1-235.e4. PubMed ID: 33451935
[TBL] [Abstract][Full Text] [Related]
40. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
Ullrich T; Arsov C; Quentin M; Laqua N; Klingebiel M; Martin O; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
